Alto Neuroscience (NYSE:ANRO) Trading Down 7.2% – Here’s Why

Alto Neuroscience, Inc. (NYSE:ANRO) was down 7.2% during mid-day trading on Tuesday . The company traded as low as $25.56 and last traded at $25.3550. Approximately 26,588 shares were traded during mid-day trading, a decline of 90% from the average daily volume of 267,385 shares. The stock had previously closed at $27.33.

Analyst Ratings Changes

Several analysts have commented on ANRO shares. Chardan Capital reaffirmed a “buy” rating and set a $30.00 price objective on shares of Alto Neuroscience in a research note on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Alto Neuroscience in a research note on Thursday, April 2nd. JonesTrading reduced their price objective on Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating for the company in a research note on Thursday, April 2nd. Robert W. Baird reduced their price objective on Alto Neuroscience from $41.00 to $38.00 and set an “outperform” rating for the company in a research note on Thursday, April 2nd. Finally, BTIG Research upped their price objective on Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Alto Neuroscience has an average rating of “Moderate Buy” and a consensus target price of $35.14.

Alto Neuroscience Trading Up 6.0%

The firm has a market capitalization of $866.63 million, a PE ratio of -12.44 and a beta of 2.01. The business has a 50 day moving average price of $21.58 and a 200-day moving average price of $16.74. The company has a current ratio of 15.69, a quick ratio of 15.69 and a debt-to-equity ratio of 0.12.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Monday, March 16th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.11. Analysts expect that Alto Neuroscience, Inc. will post -2.48 earnings per share for the current year.

Hedge Funds Weigh In On Alto Neuroscience

A number of large investors have recently modified their holdings of ANRO. Invesco Ltd. purchased a new position in Alto Neuroscience in the 1st quarter valued at approximately $67,000. AQR Capital Management LLC purchased a new position in Alto Neuroscience in the 1st quarter valued at approximately $52,000. Marshall Wace LLP increased its stake in Alto Neuroscience by 9.9% in the 2nd quarter. Marshall Wace LLP now owns 937,407 shares of the company’s stock valued at $2,062,000 after purchasing an additional 84,417 shares in the last quarter. Jane Street Group LLC purchased a new position in Alto Neuroscience in the 2nd quarter valued at approximately $240,000. Finally, Bridgeway Capital Management LLC increased its stake in Alto Neuroscience by 85.9% in the 2nd quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock valued at $119,000 after purchasing an additional 25,000 shares in the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.